

Table S1. Faculty Panelists, CMSC Consensus Conference on Neurofilament Biomarkers in MS

Bibiana Bielekova, MD	National Institutes of Health Bethesda, Maryland, USA
Ronald Booth, PhD, DCC, FCAB	University Of Ottawa Ottawa, Ontario, Canada
Peter Calabresi, MD	Johns Hopkins University Baltimore, Maryland, USA
Tanuja Chitnis, MD	Harvard Medical School Boston, Massachusetts, USA
Manuel Comabella, MD, PhD	Vall d’Hebron University Hospital Barcelona, Spain
Robert Fox, MD	Cleveland Clinic Cleveland, Ohio, USA
Mark Freedman, HBSoc, MSc, MD, CSPQ, FAAN, FRCPC	University of Ottawa, Department of Medicine Ottawa, Ontario, Canada
Roberto Furlan, MD, PhD	San Raffaele Scientific Institute Milan, Italy
Gavin Giovannoni, MD, PhD	Barts and The London School of Medicine London, England, UK
Sharmilee Gnanapavan, MD, PhD	Barts Health NHS Trust London, England, UK
Michael Khalil, MD, PhD	Medical University of Graz Graz, Austria
Joep Killestein, MD, PhD	Amsterdam University Medical Center Amsterdam, Netherlands
Jens Kuhle, MD, PhD	University Hospital Basel Basel, Switzerland
David Leppert, MD	University Hospital Basel

	Basel, Switzerland
Jan Lycke, MD, PhD	University of Gothenburg Gothenburg, Sweden
Sarah Morrow, MD, MS,FRCPC	Western University London, Ontario, Canada
Tomas Olsson, MD, PhD	Karolinska Institute Solna, Sweden
Daniel Ontaneda, MD, PhD	Cleveland Clinic Cleveland, Ohio, USA
Michael Racke, MD	The Ohio State University Columbus, Ohio, USA
Kottil Rammohan, MD	University of Miami Miami, Florida, USA
Maria Pia Sormani, PhD	University of Genoa Genoa, Italy
Simon Thebault, MD, MSc	University of Ottawa, Department of Medicine Ottawa, Ontario, Canada

Table S2. Neurofilament Consensus Statement in MS: Key Questions and Goals

Overview of neurofilament proteins	<ul style="list-style-type: none"> • Biochemistry • Importance in neurologic disease
Neurofilament assays	<ul style="list-style-type: none"> • Which assays to use • What is known about their sensitivity, specificity, reproducibility • Is NfL the primary biomarker of interest in MS? <ul style="list-style-type: none"> ○ What is the role of heavy and medium chain?
Serum versus CSF	<ul style="list-style-type: none"> • Is there a role for both CSF and serum? • If so, when would CSF assays be preferred over serum?
When/how often to measure NfL levels	<ul style="list-style-type: none"> • Cost of assays • How often should resampling be done after baseline?
Confounders/influencing factors that can raise or lower NfL levels	<ul style="list-style-type: none"> • What baseline levels mean • What increments constitute clinically meaningful change?
Clinical use of neurofilament in MS	<ul style="list-style-type: none"> • How to assess neurofilament measures in combination with other disease characteristics and clinical information
Role of neurofilament in research, and goals of ongoing/future research	<ul style="list-style-type: none"> • Standardizing neurofilament measures and values • How can NfL be combined with other existing and emerging biomarkers

Abbreviations: CSF, cerebrospinal fluid; MS, multiple sclerosis; NfL, neurofilament light chain.